Boston Scientific makes money by selling medical devices to hospitals and doctors in 127 countries. Every time a surgeon uses a WATCHMAN device to close off a part of the heart, or a doctor uses the FARAPULSE system to treat an irregular heartbeat, or a urologist uses a LithoVue scope to find a kidney stone, Boston Scientific collects revenue from that procedure. The company does not make drugs. It makes the tools that let doctors treat patients without opening them up. Those tools cover a wide range of the body, organized into two main businesses: MedSurg (gut, kidneys, nerves) and Cardiovascular (heart, blood vessels, cancer). The diagram below traces where the money goes.
Five years of financial data tell a clear story about direction. Revenue has climbed every single year, from $11.9 billion in 2021 to $20.1 billion in 2025. That is not a slow drift upward. It is a consistent acceleration. Gross margin has stayed remarkably stable throughout, hovering between 68.6% and 69.5% across all five years. That kind of stability while doubling in size is not common. It means the company is not sacrificing price or quality to grow faster.
Cash generation has followed the same upward path. Free cash flow, which is the money left over after paying to run and build the business, grew from $1.3 billion in 2021 to $3.7 billion in 2025. That is nearly three times as much real cash in four years. Operating cash flow reached $4.5 billion in 2025. These numbers show the business is not just growing on paper. It is producing more actual cash each year.
The less comfortable part of the story is debt. Net debt has risen from $7.1 billion in 2021 to $9.5 billion in 2025. Total debt on the balance sheet stood at $11.436 billion at the end of 2025. This debt exists because Boston Scientific has been buying other companies at a rapid pace, spending billions on acquisitions like Axonics, Silk Road Medical, and Relievant Medsystems. The company uses acquisitions as its primary growth engine, not just internal invention. That strategy has worked so far, with each deal adding revenue quickly. But the debt pile is real, and it is set to get much larger.
The single product driving the most excitement right now is the FARAPULSE Pulsed Field Ablation system, used to treat atrial fibrillation, which is an irregular heartbeat. It launched in the United States in early 2024 and has grown so fast that it became the dominant part of the entire Electrophysiology business unit within two years. Its rise was so powerful that it actually made an older Boston Scientific product, the POLARx cryoablation system, less valuable, forcing the company to write down the value of those assets. One new product eating another is a sign of how quickly the medical device landscape can shift.
There are four risks worth naming specifically. First, reimbursement: if Medicare or private insurers reduce what they pay for procedures using Boston Scientific devices, hospitals will buy fewer of them or demand lower prices. Second, regulation: the FDA and international agencies control whether Boston Scientific can sell each product, and a single adverse ruling can pull a product from the market. The company is also spending between $475 million and $525 million just to comply with new European Union medical device rules, a cost that has no revenue attached to it. Third, supply chain concentration: some products are made in only one or two locations, and some materials come from a single supplier. Because FDA rules require lengthy validation before switching suppliers, a disruption cannot be fixed quickly. Fourth, debt: with $11.436 billion in total debt today, and up to $11 billion more planned for the Penumbra deal, the company must keep performing well. If revenue slows or credit conditions tighten, that debt becomes harder to manage.
The company's history with litigation adds another layer to watch. The vaginal mesh lawsuits, which resulted in approximately 54,000 cases and hundreds of millions in settlements by 2021, showed what can happen when a product causes widespread patient harm. In 2025, the company recorded $194 million in litigation charges related to a separate intellectual property matter from an acquired company. Legal costs are not a hypothetical risk here. They have materialized repeatedly, and the company is substantially self-insured on product liability.